Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1274360 | 0.85 | MAPT (0.48) | MAOAMAOBMAPTGAAKMT2A | |
| SCHEMBL11756264 | 0.85 | LMNA (0.48) | ALDH1A1TSHRALOX15HSD17B10MAOA | |
| SCHEMBL13159580 | 0.82 | MAPT (0.54) | ALDH1A1TSHRALOX15HSD17B10MAOA | |
| SCHEMBL526383 | 0.82 | MAPT (0.58) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL103248 | 0.79 | CNR2 (0.58) | ALDH1A1TSHRMAPK1CYP3A4TDP1 | |
| SCHEMBL9551610 | 0.79 | ADRA2A (0.47) | ALDH1A1ALOX15HSD17B10MAPK1MAPT | |
| Hydrochloric Acid SCHEMBL9181167 | 0.79 | MAPT (0.56) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| Ammonia Solution, Strong SCHEMBL28483632 | 0.79 | MAPT (0.56) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| Ammonia Solution, Strong SCHEMBL28486254 | 0.79 | MAPT (0.56) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL856237 | 0.77 | CA1 (0.70) | ALDH1A1TSHRALOX15HSD17B10MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-11612657-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-11382979-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220175930-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2022-06-09 | — | — | US | disclosed |
| US-20220175929-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2022-06-09 | — | — | US | disclosed |
| US-20220125927-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2022-04-28 | — | — | US | disclosed |
| CN-114269719-A | Urea derivatives as CB1 allosteric modulators | RTI国际 | 2022-04-01 | — | — | CN | disclosed |
| US-11071784-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| EP-3483149-B1 | BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | YUHAN CORP (KR) | 2021-01-13 | — | — | EP | disclosed |
| US-10689331-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-23 | — | — | US | disclosed |
| US-20120004381-A1 | RAFT POLYMERISATION | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2012-01-05 | — | — | US | disclosed |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2011-10-27 | — | — | US | disclosed |
| US-7977333-B2 | Hyperpermeability; diabetic retinopathy, ischemic retinal-vein occlusion, prematurity, age-related macular degeneration | BAYER HEALTHCARE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| WO-2010083569-A1 | RAFT POLYMERISATION | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2010-07-29 | — | — | WO | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080262008-A1 | useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262009-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS ACETATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-7326703-B2 | (1,10B-Dihydro-2-(aminocarbonyl-phenyl)-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors | TIBOTEC PHARMACEUTICALS LTD (IL) | 2008-02-05 | — | — | US | disclosed |
| US-20070248624-A1 | (1,10B-Dihydro-2-(Aminocarbonyl-Phenyl)-5h-Pyrazolo[1,5-C][1,3]Benzoxazin-5-Yl)Phenyl Methanone Derivatives as Hiv Viral Replication Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175929-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | ALDH1A1 3151/4885TSHR 2733/4885ALOX15 196/4885 |
| US-11612657-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | ALDH1A1 3151/4885TSHR 2733/4885ALOX15 196/4885 |
| US-11382979-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | ALDH1A1 3151/4885TSHR 2733/4885ALOX15 196/4885 |
| US-20080262009-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS ACETATE SALTS | CYP2F1, CYP4B1, CYP3A4 | ALDH1A1 379/4885TSHR 4149/4885ALOX15 4423/4885 |
| US-20120004381-A1 | RAFT POLYMERISATION | OXGR1, FRG1, MSR1 | ALDH1A1 1653/4885TSHR 1897/4885ALOX15 370/4885 |
| US-20220175930-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | ALDH1A1 3151/4885TSHR 2733/4885ALOX15 196/4885 |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | VEGFA, PGF, FLT1 | ALDH1A1 1173/4885TSHR 1453/4885ALOX15 1036/4885 |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | ALDH1A1 3151/4885TSHR 2733/4885ALOX15 196/4885 |
| US-20220125927-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | ALDH1A1 3151/4885TSHR 2733/4885ALOX15 196/4885 |
| US-20070248624-A1 | (1,10B-Dihydro-2-(Aminocarbonyl-Phenyl)-5h-Pyrazolo[1,5-C][1,3]Benzoxazin-5-Yl)Phenyl Methanone Derivatives as Hiv Viral Replication Inhibitors | POLRMT, MAVS, DHX15 | ALDH1A1 789/4885TSHR 4879/4885ALOX15 1844/4885 |
| US-11071784-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | ALDH1A1 3151/4885TSHR 2733/4885ALOX15 196/4885 |
| US-20080262008-A1 | useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph | CSNK1A1, PRKX, PRKACA | ALDH1A1 3364/4885TSHR 3633/4885ALOX15 4165/4885 |
| US-10689331-B2 | IDO inhibitors | IDO1, IDO2, INMT | ALDH1A1 707/4885TSHR 4369/4885ALOX15 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.